Data show a decline in cystic fibrosis since introduction of prenatal carrier screening

The state of Massachusetts has offered universal newborn screening to detect cystic fibrosis (CF) since 1999. Independently, recommendations for nationwide (adult) carrier screening for CF were introduced in the U.S. around 2002, coming from the National Institutes of Health, the American College of Obstetrics and Gynecology and the American College of Medical Genetics.

Newborn screening for cystic fibrosis (much like newborn screening for other conditions), a public health service geared toward improving the lives of babies born with treatable conditions, identifies infants across the state who are at risk for disease and ensures that these infants are referred for diagnostic evaluation and (when appropriate) care. Tracking the number of infants who are diagnosed with the disease is an integral part of quality assurance of the newborn screening program.

Using the Massachusetts newborn screening data, the researchers compared two four-year periods: 1999 to 2002, just before prenatal CF carrier screening came into wide practice, and 2003 to 2006.

The number of live-born infants with CF dropped by about 50 percent from one four-year period to the next. Moreover, among the babies who were born with CF, markedly fewer had two copies of the delta F508 gene mutation, associated with a severe form of CF. The authors, who work closely with the clinician directors of the five Massachusetts CF Centers at Baystate Medical Center in Springfield; Children’s Hospital Boston; Massachusetts General Hospital; New England Medical Center; UMass Memorial Health Care in Worcester; and UMMS, are confident that the decrease is real—not an aberration of the screening program and not a normal fluctuation.

Clinical researchers have understood that a major challenge of CF newborn screening is developing treatments to maintain the health of relatively asymptomatic newborns. “Our recent observations that fewer infants are being born with CF—particularly fewer infants with a severe genotype—provides an additional challenge to researchers developing new treatments or using population data for trend analyses,” says Anne Comeau, PhD, associate professor of pediatrics at the University of Massachusetts Medical School and deputy director of the NENSP. “We should not fool ourselves into thinking that our treatments are working better than they are if the treatment may be tested on a population that was already bound to be more healthy.”

The authors hypothesize that the gradual implementation of the recommendation to offer preconception and prenatal screening in order to identify carriers of CF might have yielded a decrease in the number of births of infants with CF, particularly the type that causes the most severe disease.

“Our data cannot distinguish the reason for the reported decrease,” notes Richard Parad, MD, MPH, a newborn medicine specialist at Children’s Hospital Boston and Brigham and Womens Hospital, who co-authored the study with Jaime Hale of NENSP and Comeau. “Carrier couples may have chosen not to conceive, or they may have resorted to donor egg or sperm or to pre-implantation genetic diagnosis, or they may have decided to terminate affected pregnancies.”

CF affects all races, and is the most common autosomal recessively inherited disorder in Caucasians (about 1/3000 births). Fifty years ago, most children with CF died before they reached school age, but today, with early diagnosis and improved treatment, the median survival is 36 years.

Source: University of Massachusetts Medical School

New technique produces genetically identical stem cells
Adult cells of mice created from genetically reprogrammed cells—so-called induced pluripotent stem (IPS) stem cells—can be triggered via drug to enter an embryonic-stem-cell-like state, without the need for further genetic alteration.
CT lung cancer screening no cure-all for smokers
Screening for lung cancer with computed tomography (CT) may help reduce lung cancer deaths in current and former smokers, but it won't protect them from other causes of death associated with smoking, according to a new study published in the July issue of the journal Radiology.
Determining genetic signature of lung tumors can help guide treatment
The first U.S. clinical trial using genetic screening to identify lung tumors likely to respond to targeted therapies supports the use of those drugs as first-line treatment rather than after standard chemotherapy has failed. While the study led by Massachusetts General Hospital Cancer Center investigators found that upfront gefitinib (Iressa) treatment considerably improved the outcomes for non-small-cell-lung-cancer (NSCLC), additional research is required before such a strategy can be used for routine treatment planning. The report appears in the May 20 Journal of Clinical Oncology.
Black men appear less likely to undergo elective aneurysm repair than white men
Black men are less likely than white men to undergo elective surgery to repair abdominal aortic aneurysms, even after accounting for racial differences in rates of developing the disease, according to a report in the May issue of Archives of Surgery.
Researchers unravel heparin death mystery
An international team of researchers led by MIT has explained how contaminated batches of the blood-thinner heparin were able to slip past traditional safety screens and kill dozens of patients recently in the United States and Germany.
Study identifies mechanism underlying multidrug resistance in fungi
A team of researchers led by Anders Näär, PhD, of the Massachusetts General Hospital (MGH) Cancer Center has identified a mechanism controlling multidrug resistance in fungi. This discovery could help advance treatments for opportunistic fungal infections that frequently plague individuals with compromised immunity, such as patients receiving chemotherapy, transplant recipients treated with immunosuppressive drugs, and AIDS patients. The findings appear in the April 3 issue of Nature.
On a 'roll': Researchers devise new cell-sorting system
Capitalizing on a cell’s ability to roll along a surface, MIT researchers have developed a simple, inexpensive system to sort different kinds of cells — a process that could result in low-cost tools to test for diseases such as cancer, even in remote locations.
Gene variants may increase risk of anxiety disorders
Massachusetts General Hospital (MGH) researchers – in collaboration with scientists at the University of California at San Diego and Yale University – have discovered perhaps the strongest evidence yet linking variation in a particular gene with anxiety-related traits. In the March issue of Archives of General Psychiatry, the team describes finding that particular versions of a gene that affects the activity of important neurotransmitter receptors were more common in both children and adults assessed as being inhibited or introverted and also were associated with increased activity of brain regions involved in emotional processing.

Data show a decline in cystic fibrosis since introduction of prenatal carrier screening

Related stories:

News discussion: